CluePoints launches patient profiles as latest addition to its risk-based monitoring and data quality oversight solution
The Patient Profiles provide data in a customisable visual format
CluePoints, a U.S. provider of Risk-Based Monitoring (RBM) and Data Quality Oversight solutions for clinical trials, has introduced Patient Profiles to its rapidly expanding platform.
The powerful combination of Patient Profile reports, guided by CluePoints’ central statistical monitoring, offers a new way for clinical teams to prioritise the investigation of atypical patients in clinical trials.
Patient Profiles provides detailed insight into patient experiences and offers a more targeted approach by identifying anomalies in data and ranking patients by their relative degree of atypicality. The highly configurable Patient Profiles solution presents a set of customisable visualisation options, including the ability to visually assess a chronological view of a patient’s visit, investigational product exposure, adverse events and concomitant medications – along with any additional relevant patient information.
The solution will help enhance overall quality management, guiding study teams to quickly and effectively characterise risk signals and enable centralised medical and safety reviews within the CluePoints platform.
“The addition of Patient Profiles to CluePoints’ portfolio aligns with our vision of expanding data exploration capabilities at both the patient and site level,” commented Steve Young, chief operations officer at CluePoints.
“Reinforced by the voice of our customers, the solution will revolutionise the patient profiles review process by prioritising and illuminating ‘at risk’ patients.
“Our agile product methodology is enabling us to rapidly evolve our solutions and exceed the expectations of our customers, delivering tangible value to them. This latest addition will significantly improve the efficiency of patient data review processes because customers can target their efforts on the patients and data that matter most.”